by Riley Nolan | Jan 26, 2021 | Events, Featured, Webinars
The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. Full Agenda Here. EpiVax CEO/CSO, Annie De Groot, presented an update on...
by Danielle Medeiros | Dec 31, 2020 | Featured, News
PROVIDENCE, R.I., Dec. 31, 2020 /PRNewswire/ — EpiVax (“EpiVax”) and EpiVax Therapeutics (“EVT”) today provide an update on the advancement of their peptide-based COVID-19 vaccine, EPV-CoV-19. EPV-CoV-19, a T cell epitope-based vaccine...
by Danielle Medeiros | Dec 29, 2020 | Featured, News
PROVIDENCE, R.I., Dec. 29, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today provides an update on the advancement of the company’s peptide therapeutic immunogenicity assessment program. The PANDA (Peptide Abbreviated New Drug Application)...
by Danielle Medeiros | Dec 15, 2020 | Featured, News
PROVIDENCE, RI, December 15, 2020 /PRNewswire/ — EpiVax, Inc. reports a record-breaking year for the “ISPRI” immunogenicity screening toolkit. More pharmaceutical and biotechnology companies signed new and continuing licenses for access to the toolkit in 2020...
by Danielle Medeiros | Oct 27, 2020 | Events, Featured
EpiVax is proud to have three of our Director and Senior level scientists representing our work at the 2020 AAPS PharmSci 360 Meetings. There are several opportunities to catch up with them over the next two weeks including the following rapid fire talks: Brian...
by Danielle Medeiros | Oct 22, 2020 | Featured, News
PROVIDENCE, RI, October 22, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) and CUBRC, Inc. (“CUBRC”) announced today that they have been awarded a two-year, $1.1 million contract from the Office of Generic Drugs (OGD) in the Center of Drug Evaluation and Research...
